000534.SZ深圳证券交易所 · 主板 Main
Wedge Industrial 万泽股份
Biologics 生物制品
¥21.80−¥0.84 · −3.71%
Open 开盘
¥22.71
High 最高
¥22.84
Low 最低
¥21.65
Prev Close 昨收
¥22.64
Volume 成交量
1,506.6万股
Turnover 成交额
¥3.34亿
Mkt Cap 总市值
¥111亿
P/E 市盈率
54.7×
Recent Activity 近期动态All Filings 全部公告 →
12 significant filings since 1 Jun 2026: 1 on share pledge, 6 on equity incentive and 3 on guarantee or financial assistance, and 2 other kinds. The latest, on 1 Sep 2026: 万泽股份关于公司2025年股权激励计划首次授予限制性股票第一个解除限售期解除限售股份上市流通的提示性公告.
自 1 Jun 2026 起有 12 份重大公告：share pledge 1 份、equity incentive 6 份、guarantee or financial assistance 3 份，另有 2 类。最新一份（1 Sep 2026）：万泽股份关于公司2025年股权激励计划首次授予限制性股票第一个解除限售期解除限售股份上市流通的提示性公告。
Price History 价格走势
7,409 trading days 个交易日 · High 最高 ¥47.65 · Low 最低 ¥1.1210.0020.0030.0040.00
Volume 成交量
7,541.5万
19942001200920192026
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Biologics 生物制品 · 58 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥111亿 | ¥105亿 | 28th highest of 58 · 58 家中第 28 高 | |
| Trailing P/E 市盈率 | 54.7x | 31.9x | 15th highest of 35 · 35 家中第 15 高 | |
| P/B 市净率 | 5.9x | 3.0x | 13th highest of 56 · 56 家中第 13 高 | |
| Revenue Growth 营收增速 | 6.6% | 2.5% | 27th highest of 58 · 58 家中第 27 高 | |
| Profit Growth 净利增速 | 5.0% | 6.4% | 27th lowest of 58 · 58 家中第 27 低 | |
| Gross Margin 毛利率 | 71.1% | 70.5% | 27th highest of 58 · 58 家中第 27 高 | |
| Net Margin 净利率 | 17.1% | 8.9% | 24th highest of 58 · 58 家中第 24 高 | |
| Return on Equity 净资产收益率 | 7.5% | 1.6% | 7th highest of 57 · 57 家中第 7 高 | |
| Debt to Assets 资产负债率 | 57.7% | 24.1% | 7th highest of 58 · 58 家中第 7 高 | |
| Grade Score 评级得分 | 45 | 50 | 22nd lowest of 54 · 54 家中第 22 低 |
Statement figures are for the period to 30 Jun 2026, filed by 58 of 58 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，58 家同业中 58 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Biokin Pharmaceutical 百利天恒 | ¥989亿 | — | 21.5x | 9.4% | -874.0% | -28.9% | E |
| Remegen 荣昌生物 | ¥651亿 | 11.2x | 7.8x | 433.1% | 79.7% | 78.4% | A |
| Gan & Lee 甘李药业 | ¥442亿 | 38.4x | 3.8x | 7.6% | 27.4% | 5.2% | C |
| Junshi Biosciences 君实生物 | ¥358亿 | — | 6.0x | 45.2% | -2.4% | 0.4% | D |
| Sunshine Guojian Pharmaceutical 三生国健 | ¥351亿 | 11.4x | 4.1x | 34.8% | 42.5% | 4.3% | C |
| Shanghai RAAS Blood Products 上海莱士 | ¥335亿 | 27.7x | 1.0x | -18.8% | 20.6% | 2.0% | D |
| Chongqing Zhifei Biological Products 智飞生物 | ¥310亿 | — | 2.1x | -18.4% | -20.4% | -5.2% | D |
| Changchun High-Tech Industry 长春高新 | ¥288亿 | — | 1.3x | -16.1% | 7.9% | 2.1% | C |
| Beijing Tiantan Biological Products 天坛生物 | ¥242亿 | 31.9x | 2.0x | -16.6% | 16.0% | 2.5% | D |
| Hualan Biological Engineering 华兰生物 | ¥241亿 | 29.8x | 2.2x | -12.9% | 25.2% | 3.3% | C |
| Walvax Biotechnology 沃森生物 | ¥218亿 | 115.2x | 3.1x | -27.7% | 5.5% | 0.7% | D |
| Cansino Biologics 康希诺 | ¥214亿 | 525.9x | 4.3x | 43.8% | -0.1% | -0.0% | D |
| Amoytop 特宝生物 | ¥211亿 | 19.5x | 6.8x | 21.6% | 25.9% | 13.2% | C |
| Acrobiosystems 百普赛斯 | ¥203亿 | 112.5x | 7.6x | 29.0% | 19.7% | 3.6% | B |
| Wedge Industrial 万泽股份 | ¥111亿 | 54.7x | 5.9x | 6.6% | 17.1% | 7.5% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。